Who are BHV-3500 (zavegepant)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zavzpret, Nurtec Odt, rimegepant 75 mg ODT, Placebo-Matching Atogepant, Placebo to telcagepant tablets, Placebo to Telcagepant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bhv-3500-zavegepant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BHV-3500 (zavegepant) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BHV-3500 (zavegepant) (bhv-3500-zavegepant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CGRP receptor antagonist. Area: Neuroscience.

discontinued CGRP receptor antagonist CGRP receptor (calcitonin gene-related peptide receptor) Neuroscience Live · refreshed every 30 min

Target snapshot

BHV-3500 (zavegepant) (bhv-3500-zavegepant) — Pfizer Inc.. Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BHV-3500 (zavegepant) TARGET	bhv-3500-zavegepant	Pfizer Inc.	discontinued	CGRP receptor antagonist	CGRP receptor (calcitonin gene-related peptide receptor)
Zavzpret	zavegepant	Pfizer	marketed	CGRP receptor antagonist	Calcitonin gene-related peptide (CGRP) receptor	2023-01-01
Nurtec Odt	Rimegepant Sulfate	Pfizer	marketed	CGRP receptor antagonist	Calcitonin gene-related peptide (CGRP) receptor	2020-01-01
rimegepant 75 mg ODT	rimegepant-75-mg-odt	Pfizer	marketed	CGRP receptor antagonist	CGRP receptors
Placebo-Matching Atogepant	Placebo-Matching Atogepant	AbbVie	phase 3	CGRP receptor antagonist	CGRP receptor (calcitonin gene-related peptide receptor)
Placebo to telcagepant tablets	Placebo to telcagepant tablets	Merck Sharp & Dohme LLC	phase 3	CGRP receptor antagonist	CGRP receptor
Placebo to Telcagepant	Placebo to Telcagepant	Merck Sharp & Dohme LLC	phase 3	CGRP receptor antagonist	CGRP receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CGRP receptor antagonist class)

Merck Sharp & Dohme LLC · 3 drugs in this class
Pfizer · 3 drugs in this class
Biohaven Therapeutics Ltd. · 2 drugs in this class
AbbVie · 1 drug in this class
Samsung Medical Center · 1 drug in this class
Pfizer Inc. · 1 drug in this class
Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BHV-3500 (zavegepant) — Competitive Intelligence Brief. https://druglandscape.com/ci/bhv-3500-zavegepant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab